Treatment of Calciphylaxis with Severe Refractory or Poorly Controlled Hyperparathyroidism
Calciphylaxis in the setting of severe, refractory, or poorly controlled hyperparathyroidism represents a distinct clinical challenge. The underlying mineral metabolism disorder directly shapes both the choice of intervention and the targets that define a successful response.
This protocol applies to patients with calciphylaxis whose hyperparathyroidism is severe, refractory, or remains poorly controlled — a comorbidity that must be addressed as part of the overall management strategy.
The approach centers on optimizing parathyroid hormone control through pharmacologic means, with a surgical option reserved for the most severe and refractory presentations. The specific agent, the conditions governing each choice, and the full management algorithm are available in the complete protocol.
Success is defined by maintaining calcium, phosphorus, and parathyroid hormone within target ranges.
References
- DOI: 10.1053/j.ajkd.2022.06.011
- Optimizing mineral bone disease (maintaining target ranges of calcium, phosphorus, and parathyroid hormone), replacing activated vitamin D with cinacalcet to target the goal parathyroid hormone level, and parathyroidectomy for severe refractory hyperparathyroidism are reasonable approaches, as outlined by the KDIGO guideline.
- Anecdotally, we would favor prioritizing pharmacotherapy with sodium thiosulfate, withdrawal of risk-inducing medications (warfarin, vitamin D, and calcium-based binders), cautious surgical debridement, cinacalcet or parathyroidectomy for those with poorly controlled hyperparathyroidism, and pain control.